1678-68-8

Usage

Chemical Properties

Yellow Solid

InChI:InChI=1/C9H17NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h7-8H,2-6,10H2,1H3/t7-,8-

Upstream product

• 64-17-5 ethanol 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 
• 51498-33-0 ethyl 4-amino-1-cyclohexanecarboxylate 
• 94-09-7 p-aminoethylbenzoate 
• 27960-59-4 trans-4-aminocyclohexanecarboxylic acid hydrochloric acid 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 

Downstream Products

• 117112-22-8 C₁₃H₂₄Cl₃N₂O₃P 
• 117112-30-8 ethyl N-phosphoryl-trans-4-aminocyclohexanecarboxylate 
• 117112-29-5 ethyl N-phosphoryl-trans-4-aminocyclohexanecarboxylate 
• 117112-32-0 ethyl N-phosphoryl-trans-4-aminocyclohexanecarboxylate 
• 256477-73-3 ethyl trans-4-{[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino}cyclohexanecarboxylate 
• 1242419-25-5 trans-4-{4-[8-(1-hydroxy-1-methyl-ethyl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethyl ester 
• 1242419-18-6 trans-4-[4-(8-benzyloxyimidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-cyclohexanecarboxylic acid ethyl ester 
• 1263479-95-3 4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethyl ester 
• 181308-57-6 trans-(4-formyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 1467-84-1 ((1R,4R)-4-aminocyclohexyl)methanol 
• 33059-86-8 N--N'-<2-chlor-aethyl>-harnstoff 
• 78431-91-1 4-[Bis-(2-hydroxy-ethyl)-amino]-cyclohexanecarboxylic acid ethyl ester 
• 117112-21-7 C₁₃H₂₄Cl₃N₂O₃P 
• 117112-34-2 ethyl N-(N'N'-dimethylamido-N''-cyclohexylamido)-phosphoryl-cis-4-aminocyclohexanecarboxylate 

Relevant academic research and scientific papers

NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

A structure-activity analysis of biased agonism at the dopamine D2 receptor

Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs. A number of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia. As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor. We have generated SAR based on a novel D2R partial agonist, tert-butyl (trans-4-(2-(3,4-dihydroisoquinolin- 2(1H)-yl)ethyl)cyclohexyl)carbamate (4). This ligand shares structural similarity to cariprazine (2), a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points. We synthesized a number of derivatives of 4 with subtle structural modifications, including incorporation of cariprazine fragments. By combining pharmacological profiling with analytical methodology to identify and to quantify bias, we have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group containing the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer

A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK). Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity. Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors. Compound 49 achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd. Compounds 36 and 49 show favorable potency and PK characteristics in preclinical species indicative of suitability for further development.

JNK modulators

Compounds of formula I modulate JNK: wherein the variables are as defined herein.

METHOD FOR PRODUCING ALKYL TRANS-4-AMINOCYCLOHEXANECARBOXYLATE HYDROCHLORIDE

PROBLEM TO BE SOLVED: To provide a method for industrially advantageously producing a high-purity alkyl trans-4-aminocyclohexanecarboxylate hydrochloride. SOLUTION: Alkyl 4-aminocyclohexanecarboxylates in (50/50) to (0/100) cis/trans isomer ratio are reacted with an amine hydrochloride in a 1-10C aliphatic alcohol and crystallization is then carried out. Thereby, the alkyl trans-4-aminocyclohexanecarboxylate hydrochloride is produced.

Synthesis of analogues of N (2 chloroethyl) N' trans 4 methylcyclohexyl) N nitrosourea for evaluation as anticancer agents

The superior activity of N (2 chloroethyl) N' (trans 4 methylcyclohexyl) N nitrosourea (MeCCNU) against advanced murine Lewis lung carcinoma in comparisons with the cis form and other nitrosoureas prompted the synthesis of a number of MeCCNU analogues, including several cis trans pairs. The methyl group was replaced by a variety of substituents (CO2H, CH2CO2H, CO2Me, CH2OAc, CH2Cl, OMe); the trans 3 methylcyclohexyl, cis 2 methyl 1,3 dithian 5 yl, cis and trans 2 methyl 1,3 dithian 5 yl tetraoxide, and 1 methylhexyl (open chain) analogues were also prepared. Preliminary tests against murine leukemia L1210 revealed therapeutic indices (ED50/LD10) ranging from 0.26 to 0.79; all but 3 analogues effected 50% cure rates at nontoxic doses, the open chain analogue being one of the least active. In terms of therapeutic index, diequatorial (trans 4) isomers were, with one exception, as active as or, in 4 of the 8 examples, somewhat more active than the corresponding axial equatorial (cis 4) isomers. In this series, 4 of the 5 2-fluoroethyl analogues prepared were clearly inferior to the corresponding 2 chloroethyl analogues.